Connexion
Connexion
Ou se connecter avec
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Inscription
Ou se connecter avec
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

STEMLINE THERAPEUTICS, INC.

Temps Différé Nasdaq  - 
- USD   -.--%
11/08L'Elacestrant de Menarini Groupֆa reçu une revue prioritaire de la FDA américaine pour les patientes atteintes d'un cancer du sein avancé ou métastatique ER+/HER2-.
CI
2019Les valeurs à suivre à Wall Street
RE
SynthèseActualitésSociétéFonds 


Aucune donnée



Copyright © 2009 Morningstar. All Rights Reserved. The information, data and opinions expressed (“Information”) and contained herein: (1) are proprietary to Morningstar and/or its content providers and are not intended to represent investment advice or recommendation to buy or sell any security; (2) may not be copied or distributed without express license to do so; and (3) are not warranted to be accurate, complete or timely. Morningstar reserve its rights to charge for access to these Ratings and/or Rating report. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this Rating, Rating Report or Information contained therein.
Secteur et Concurrence
Var. 1janvCapi. (M$)
STEMLINE THERAPEUTICS, INC.0.00%570
GILEAD SCIENCES, INC.-15.04%79 050
VERTEX PHARMACEUTICALS31.85%75 091
REGENERON PHARMACEUTICALS, INC.9.08%73 961
BIONTECH SE-48.18%32 467
WUXI APPTEC CO., LTD.-39.54%29 383